Advances in neurofibromatosis 2 (NF2): A workshop report

Journal of Neurogenetics

Volumn 14, Issue 2, 2000, Pages 63-106

  Lim, David J ^a   Rubenstein, Allan E ^a   Evans, D Gareth ^a   Jacks, Tyler ^a   Seizinger, Bernd G ^a   Baser, Michael E ^a   Beebe, David ^a   Brackmann, Derald E ^a   Chiocca, E Antonio ^a   Fehon, Richard G ^a   Giovannini, Marco ^a   Glazer, Robert ^a   Gusella, James F ^a   Gutmann, David H ^a   Korf, Bruce ^a   Lieberman, Frank ^a   Martuza, Robert ^a   McClatchey, Andrea I ^a   Parry, Dilys M ^a   Pulst, Stefan M ^a   Ramesh, Vijaya ^a   Ramsey, W Jay ^a   Ratner, Nancy ^a   Rutkowski, J Lynn ^a   Ruttledge, Martin ^a   Weinstein, David E ^a   more..

^a HOUSE EAR INSTITUTE   (United States)

Author keywords

Merlin; NF2, neurofibromatosis 2; Schwann cells; Vestibular schwannomas

Indexed keywords

GENE EXPRESSION; GENE MUTATION; GENOTYPE; HUMAN; MEDICAL RESEARCH; MOLECULAR BIOLOGY; NEUROFIBROMATOSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

FALCO COLUMBARIUS;

EID: 0033917411     PISSN: 01677063     EISSN: None     Source Type: Journal    
DOI: 10.3109/01677060009083477     Document Type: Review

References (95)

1. Abaza, M.M., Makariou, E., Armstrong, M. and Lalwani, A.K. (1996). Growth rate characteristics of acoustic neuromas associated with neurofibromatosis type 2. Laryngoscope, 106, 694-699.
2. Adamson, P.C., Hannah, A.L., Blaney, S.M., Kitchen, B.J., Murphy, R.F., Gillespie, A.F., Whitcomb, P.G., Cropp, G.F. and Balis, F.M. (1999). A pediatric phase 1 trial and pharmacokinetic (PK) study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101. Proc. Amer. Assoc. Cancer Res., 40, 4776.
3. Akagi, K., Sandig, V., Vooijs, M., Van der Valk, M., Giovannini, M., Strauss, M. and Berns, A. (1997). Cre-mediated somatic site-specific recombination in mice. Nucleic Acids Research, 25(9), 1766-1773.
4. Baser, ME., Ragge, N.K., Riccardi, V., Janus, T., Gantz, B. and Pulst, S.M. (1996). Phenotypic variability in monozygotic twins with neurofibromatosis 2. Am. J. Med. Genet., 64, 563-567.
5. Baser, M.E., Mautner, V., Thakkar, S.D. and Kluwe, L. (1998). The natural history of neurofibromatosis 2. Am. J. Hum. Genet., Suppl. 63 (4 Suppl), A63.
6. Baser, M.E., Kluwe, L. and Mautner, V.F. (1999). Germ-line NF2 mutations and disease severity in neurofibromatosis type 2 patients with retinal abnormalities. Am. J. Hum Genet., 64(4), 1230-1233.
7. Bianchi, A., Mitsunaga, S.I., Cheng, J.Q., Klein, W.M., Jhanwar, S.C., Seizinger, B., Kley, N., Klein-Szanto, A.J. and Testa, J.R. (1995). High frequency of inactivating; mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc. Natl. Acad. Sci. USA, 92, 10854-10858.
8. Birch, B., Johnson, J.P., Parsa, A., Desai, R.D., Yoon, J.T., Lycette, C.A., Li, Y.M. and Bruce, J.N. (1996). Frequent type 2 neurofibromatosis gene transcript mutations in sporadic intramedullary spinal cord ependymomas. Neurosurgery, 39, 135-140.
9. Bischoff, J.R., Kirn, D.H., Williams, A., Heise, C, Horn, S., Muna, M., Ng, L., Nye, J.A., Sampson-Johannes, A., Fattaey, A. and McCormick, F. (1996). An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science, 274, 373-376.
10. Blessing, T., Remy, J.S. and Behr, J.P. (1998). Monomolecular collapse of plasmid DNA into stable virus-like particles. Proc. Natl. Acad. Sci. USA, 95, 1427-1431.
11. Bobo, R.H., Laske, D.W., Akbasak, A., Morrison, P.F., Dedrick, R.L. and Oldfield, E.H. (1994). Convection-enhanced delivery of macromolecules in the brain. Proc. Natl. Acad. Sci. USA, 91, 2076-2080.
12. Chase, M., Chung, R.Y. and Chiocca, E.A. (1998). An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nature Biotechnology, 16, 444-448.
13. Chiocca, E.A. and Breakefield, X.O. (1998). Gene therapy for neurological disorders and brain tumors, Humana Press, Totowa, NJ.
14. Defer, G.L., Adle-Biassette, H., Ricolfi, F., Martin, L., Authier, F.J., Chomienne, C. and Degos, J.D. (1997). All trans retinoic acid in relapsing malignant gliomas: Clinical and radiological stabilization associated with the appearance of intratumoral calcifications. J. Neurooncol., 34(2), 169-177.
15. Deguen, B., Merel, P., Goutebroze, L., Giovannini, M., Reggio, H., Arpin, M. and Thomas, G. (1998). Impaired interaction of naturally occurring mutant NF2 protein with actin-based cytoskeleton and membrane. Hum. Mol. Genet., 7, 217-226.
16. den Bakker, M.A., Riegman, P.H., Hekman, R.A., Boersma, W., Janssen, P.J., van der Kwast, T.H. and Zwarthoff, E.C. (1995). The product of the NF2 tumour suppressor gene localizes near the plasma membrane and is highly expressed in muscle cells. Oncogene, 10, 757-763.
17. Evans, D.G., Huson, S.M., Donnai, D., Neary, W., Blair, V., Newton, V. and Harris, A.E. (1992). A clinical study of type 2 neurofibromatosis. Q. J. Med., 84, 603-618.
18. Evans, D.G.R., Mason, S., Huson, S.M., Ponder, M., Harding, A.E. and Strachan, T. (1997). Spinal and cutaneous schwannomatosis is a variant form of type 2 neurofibromatosis: A clinical and molecular study. J. Neurol. Neurosurg. Psychiat., 62, 361-366.
19. Evans, D.G.R., Trueman, L., Wallace, A., Collins, S. and Strachan, T. (1998). Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): Evidence for more severe disease associated with truncating mutations. J. Med. Genet., 35, 450-455.
20. Fehon, R.G., Oren, T., LaJeunesse, D.R., Melby, T.E. and McCartney, B.M. (1997). Isolation of mutations in the Drosophila homologues of the human neurofibromatosis 2 and yeast CDC42 genes using a simple and efficient reverse-genetic method. Genetics, 146, 245-252.
21. Fong, T.A., Shawver, L.K., Sun, L., Tang, C., App, H., Powell, T.J., Kim, Y.H., Schreck, R., Wang, X., Risau, W., Ullrich, A., Hirth, K.P. and McMahon, G. (1999). SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res., 59(1), 99-106.
22. Fraefel, C., Song, S., Lim, F., Lang, P., Yu, L., Wang, Y., Wild, P. and Geller, A.I. (1996). Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J. Virol. 70, 7190-7197.
23. Furth, P.A., St. Onge, L., Boger, H., Grass, P., Gossen, M., Kistner, A., Bujard, H. and Hennighausen, L. (1994). Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. Proc. Natl. Acad. Sci. USA, 91(20), 9302-9306.
24. Giovannini, M., Robanus-Maandag, E., Niwa-Kawakita, M., van der Valk, M., Woodruff, J., Goutebroze, L., Merel, P., Berns, A. and Thomas, G. (1999). Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein. Genes Dev., 13, 978-986.
25. Gonzalez-Agosti, C, Xu, L., Pinney, D., Beauchamp, R., Hobbs, W., Gusella, J. and Ramesh, V. (1996). The Merlin tumor suppressor localizes preferentially in membrane ruffles. Oncogene, 13, 1239-1247.
26. Gusella, J., Ramesh, V., MacCollin, M. and Jacoby, L.B. (1996). Neurofibromatosis 2: Loss of Merlin's protective spell. Current Opinion in Genetics and Development, 6, 87-92.
27. Gutmann, D.H., Aylsworth, A., Carey, J.C., Korf, B., Marks, J., Pyeritz, R.E., Rubenstein, A. and Viskochil, D. (1997). The diagnostic evaluation and multi-disciplinary management of neurofibromatosis 1 and neurofibromatosis 2. J. Am. Med. Assoc., 278, 51-7.
28. Gutmann, D.H., Geist, R.T., Xu, H.M., Kim, J.S. and Saporito-Irwin, S. (1998). Defects in neurofibromatosis 2 protein function can arise at multiple levels. Hum. Molec. Genet., 7, 335-345.
29. Harris, S.R. and Thorgeirsson, U.P. (1998). Tumor angiogenesis: Biology and therapeutic prospects. In Vivo, 12, 563-570.
30. Howard, M., Rizzell, R.A. and Bedwell, D.M. (1996). Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nature Medicine, 2, 467-469.
31. Huynh, D.P. and Pulst, S.M. (1996). Neurofibromatosis 2 antisense oligodeoxynucleotides induce reversible inhibition of schwannomin synthesis and cell adhesion in STS26T and T98G cells. Oncogene, 13, 73-84.
32. Huynh, D.P., Mautner, V., Baser, M.E., Stavrou, D. and Pulst, S.M. (1997). Immunohistochemical detection of schwannomin and neurofibromin in vestibular schwannomas, ependymomas and meningiomas. J. Neuropath. Exp. Neurol., 56, 382-390.
33. Jacoby, L.B., MacCollin, M., Barone, R., Ramesh, V. and Gusella, J. (1996). Frequency and distribution of NF2 mutations in schwannomas. Genes Chromosome Cancer, 17, 45-55.
34. Jacoby, L.B., Jones, D., Davis, K., Kronn, D., Short, M.P., Gusella, J. and MacCollin, M. (1997). Molecular analysis of the NF2 tumor suppressor in schwannomatosis. Am. J. Hum. Genet., 61(6), 1293-1302.
35. Jooss, K., Yang, Y. and Wilson, J.M. (1996). Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung. Hum. Gene Therapy, 7, 1555-1566.
36. Kanter, W.R., Eldridge, R., Fabricant, R., Allen, J.C. and Koerber, T. (1980). Central neurofibromatosis with bilateral acoustic neuroma, genetic, clinical and biochemical distinctions from peripheral neurofibromatosis. Neurology, 30, 851-859.
37. Kluwe, L., Bayer, S., Baser, M.E., Hazim, W., Haase, W., Funsterer, C. and Mautner, V.F. (1996). Identification of NF2 germ-line mutations and comparison with neurofibromatosis 2 phenotypes. Hum. Genet., 98, 534-538.
38. Koltover, I., Salditt, T., Radler, J.O. and Safinya, C.R. (1998). An inverted hexagonal phase of cationic liposome-DNA complexes related to DNA release and delivery, Science, 281, 78-81.
39. Kuhn, R., Schwenk, F., Aguet, M. and Rajewsky, K. (1995). Inducible gene targeting in mice. Science, 269, 1427-1429.
40. Kyritsis, A.P. (1996). Chemotherapy for meningiomas. J. Neurooncol., 29, 269-272.
41. LaJeunesse, D.R., McCartney, B.M. and Fehon, R.G. (1998). Structural analysis of Drosophila Merlin reveal functional domains important for growth control and subcellular localization. J. Cell Biol., 141(7), 1589-1599.
42. MacCollin, M. NF2 germline mutation map, initially compiled June, 1995, revised November, 1996 accessed on the World Wide Web at http://neuro-www.mgh.harvard.edu/neurowebforum/NeurofibromatosisMenu.html. References for the map, including unpublished sources of information, are listed at the map site.
43. MacCollin, M., Woodfin, W., Kronn, D. and Short, M.P. (1996). Schwannomatosis: A clinical and pathological study. Neurology, 46, 1072-1079.
44. Mautner, V.F., Tatagiba, M., Lindenau, M., Funsterer, C., Pulst, S.M., Baser, M.E., Kluwe, L. and Zanella, F.E. (1995). Spinal tumors in patients with neurofibromatosis 2: MR imaging study of frequency, multiplicity, and variety. AJR Am. J. Roentgenol., 165, 951-955.
45. Mautner, V.F., Lindenau, M., Baser, M.E., Hazim, W., Tatagiba, M., Haase, W., Samii, M., Wais, R. and Pulst, S.M. (1996). The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery, 38, 880-885.
46. Mautner, V.F., Lindenau, M., Baser, M.E., Kluwe, L. and Gottschalk, J. (1997). Skin abnormalities in neurofibromatosis 2. Arch. Dermatol., 133, 1539-1543.
47. McCartney, B.M. and Fehon, R.G. (1996). Distinct cellular and subcellular patterns of expression imply distinct functions for the Drosophila homologues of moesin and the neurofibromatosis 2 tumor suppressor, merlin. J. Cell Biol., 133, 843-852.
48. McClatchey, A.I., Saotome, I., Ramesh, V., Gusella, J.F. and Jacks, T. (1997). The Nf2 tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation. Genes Dev., 11, 1253-1265.
49. McClatchey, A.I., Saotome, L, Mercer, K., Crowley, D., Gusella, J.F., Bronson, R.T. and Jacks, T. (1998). Mice heterozygous for a mutation at the NF2 tumor suppressor locus develop a range of highly metastic tumors. Genes Dev., 12, 1121-1133.
50. Messing, A., Behringer, R.R., Wrabetz, L., Hammang, J.P., Lemke, G., Palmiter, R.D. and Brinster, R.L. (1994). Hypomyelinating peripheral neuropathies and schwannomas in transgenic mice express inf SV40 T-antigen. J. Neurosci., 14, 3533-3539.
51. Miklos, G.L.G. and Rubin, G.M. (1996). The role of the genome project in determining gene function: Insights from model organisms. Cell, 86, 521-529.
52. Miller, N. and Whelan, J. (1997). Progress in transcriptionally targeted and regulatable vectors for genetic therapy. Human Gene Therapy, 8, 803-815.
53. Minchinton, A.I., Fryer, K.H., Wendt, K.R., Clow, K.A. and Hayes, M.M. (1996). The effect of thalidomide on experimental tumors and metastases. Anticancer Drugs, 7(3), 339-343.
54. Monia, B.P., Johnston, J.F., Sasmor, H. and Cummins, L.L. (1996). Nuclease resistance and antisense activity of modified oligonucleotides targeted to Ha-ras. J. Biol. Chem., 271, 14533-14540.
55. Mukhopadhyay, T. and Roth, J.A. (1996). Antisense regulation of oncogenes in human cancer. Critical Reviews in Oncogenesis, 7, 151-190.
56. Murthy, A., Gonzalez-Agosti, C., Cordero, E., Pinney, D., Candia, C., Solomon, F., Gusella, J. and Ramesh, V. (1998). NHE-RF, a regulatory cofactor for Na(+)-H(+) exchange, is a common interactor for merlin and ERM (MERM) proteins. J. Biol. Chem., 273, 1273-1276.
57. Naldini, L., Blomer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F.H., Verma, I.M. and Trono, D. (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science, 272, 263-267.
58. Neurofibromatosis Conference Statement. National Institutes of Health Consensus Development Conference (1988). Arch. Neurol., 45, 575-578.
59. Parry, D.M., Eldridge, R., Kaiser-Kupfer, M.I., Bouzas, E.A., Pikus, A. and Patronas, N. (1994). Neurofibromatosis 2 (NF2): Clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am. J. Med. Genet., 52, 450-491.
60. Parry, D.M., MacCollin, M., Kaiser-Kupfer, M.I., Pulaski, K., Nicholson, H.S., Bolesta, M.D., Eldridge, R. and Gusella, J.F. (1996). Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am. J. Hum. Genet., 59, 529-539.
61. Paulus, W., Baur, I., Boyce, F.M., Breakefield, O.X. and Reeves, S.A. (1996). Self-contained, tetracycline-regulated retroviral vector system for gene delivery to mammalian cells. J. Virology, 70, 62-67.
62. Pelton, P.D., Sherman, L.S., Rizvi, T.A., Marchionni, M.A., Wood, P., Friedman, R.A. and Ratner, N. (1998). Ruffling membrane, stress fiber, cell spreading and proliferation abnormalities in human Schwannoma cells. Oncogene, 17(7), 2195-2209.
63. Phuphanich, S., Scott, C., Fischbach, A.J., Langer, C. and Yung, W.K. (1997). All-trans retinoic acid: A phase II Radiation Therapy Oncology Group study (RTOG 91-13) in patients with recurrent malignant astrocytoma. J. Neurooncol., 34(2), 193-200.
64. Pulst, S.M., Rouleau, G.A., Fain, P. and Sieb, J.P. (1993). Familial meningioma is not allelic to NF2. Neurology, 43, 2096-2098.
65. Rainov, N.G., Zimmer, C., Chase, M., Kramm, C.M., Chiocca, E.A., Weissleder, R. and Breakefield, X.O. (1995). Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain neoplasms. Human Gene Therapy, 6, 1543-1552.
66. Reczek, D., Berryman, M. and Bretscher, A. (1997). Identification of EBP50: A PDZ-containing phosphoprotein that associates with members of the ezrin-radixin-moesin family. J. Cell Biol., 139, 169-179.
67. Rivera, V.M., Clackson, T., Natesan, S., Pollock, R., Amara, J.F., Keenan, T., Magari, S.R., Phillips, T., Courage, N.L., Cerasoli Jr., F., Holt, D.A. and Gilman, M. (1996). A humanized system for pharmacological control of gene expression. Nature Medicine, 2, 1028-1032.
68. Rizvi, N.A., Marshall, J.C., Ness, E., Yoe, J., Gill, G.M., Truglia, J.A., Loewen, G.R., Jaunakais, D., Ulm, E.H. and Hawkins, M.J. (1998). Phase 1 study of 9-cis-retinoic acid (ALRT 1057 capsules) in adults with advanced cancer. Clin. Cancer Res., 4, 1427-1442.
69. Rouleau, G.A., Merel, P., Lutchman, M., Sanson, M., Zucman, J., Marineau, C., Hoang-Xuan, K., Demczuk, S., Desmaze, C. and Plougastel, B. (1993). Alteration in a new gene encoding a putative membrane organizing protein causes neurofibromatosis type 2. Nature, 363, 515-521.
70. Rouleau, G., Seizinger, B.R. and Ozelius, L.G. (1987). Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22. Nature, 329, 246-248.
71. Russell, D.W. and Hirata, R.K. (1998). Human gene targeting by viral vectors. Nature Genetics, 18, 325-330.
72. Ruttledge, M.H., Andermann, A.A., Phelan, C.M., Claudio, J.O., Han, F.Y., Chretien, N., Rangaratnam, S., MacCollin, M., Short, P., Parry, D., Michels, V., Riccardi, V.M., Weksberg, R., Kitamura, K., Bradburn, J.M., Hall, B.D., Propping, P. and Rouleau, G.A. (1996). Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am. J. Hum. Genet., 59, 331-342.
73. Sainz, J., Huynh, D.P., Figueroa, K., Ragge, N.K., Baser, M.E. and Pulst, S.M. (1994). Mutations of the neurofibromatosis type 2 gene and lack of the gene product in vestibular schwannomas. Hum. Mol. Genet., 6, 885-891.
74. Samid, D., Hudgins, W.R., Shack, S., Liu, L., Prasanna, P. and Myers, C.E. (1997). Phenylacetate and phenylbutyrate as novel differentiation inducers. Adv. Exp. Med. Biol., 400A, 501-505.
75. Scherer, S.S. and Gutmann, D.H. (1996). Expression of the neurofibromatosis 2 tumor suppressor gene product, merlin, in Schwann cells. J. Neurosci. Res., 46, 595-605.
76. Schiedner, G., Morral, N., Parks, R.J., Wu, Y., Koopmans, S.C., Langston, C., Graham, F.L., Beaudet, A.L. and Kochanek, S. (1998). Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nature Genetics, 18, 180-183.
77. Schrell, U.M., Rittig, M.G., Koch, U.H., Marschalek, R., Anders, M., Kiesewetter, F. and Fahlbusch, R. (1997). Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J. Neurosurg., 86(5), 840-844.
78. Scoles, D.R., Huynh, D.P., Morcos, P.A., Coulsell, E.R., Robinson, N.G., Tamanoi, F. and Pulst, S.M. (1998). Neurofibromatosis 2 tumour suppressor schwannomin interacts with beta II-spectrin. Nature Genetics, 18, 354-359.
79. Seizinger, B.R., Martuza, R.L. and Gusella, J.F. (1986). Loss of genes on chromosome 22 in tumorigenesis of human acoustic neuroma. Nature, 322, 644-647.
80. Sekido, Y., Pass, H.I., Bader, S., Mew, D.J., Christman, M.F., Gazdar, A.F. and Minna, J.D. (1995). Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res., 55, 1227-1231.
81. Shannah, S.M., Alberta, J.A., Giannobile, W.V., Guha, A., Kwon, Y.K., Carroll, R.S., Black, P.M. and Stiles, C.D. (1997). Detection of platelet-derived growth factor receptors on human meningiomas. Cancer Res., 57, 4141-4147.
82. Shawver, L.K., Schwartz, D.P., Mann, E., Chen, H., Tsai, J., Chu, L., Longhi, M., Meredith, S., Germain, L., Jacobs, J.S., Tang, C., Ullrich, A., Berens, M.E., Hersh, E., McMahon, G., Hirth, K.P. and Powell, T.J. (1997). Inhibition of platelet derived growth factor mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl] 5-methylisoxazole-4-carboxamide. Clin. Cancer Res., 3, 1167-1177.
83. Sherman, L., Xu, H.M., Geist, R.T., Saporito-Irwin, S., Howells, N., Ponta, H., Herrlich, P. and Gutmann, D.H. (1997). Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene, 15, 2505-2509.
84. Stangl, A.P., Wellenreuther, R., Lenartz, D., Kraus, J.A., Menon, A.G., Schramm, J., Wiestler, O.D. and von Deimling, A. (1997). Clonality of multiple meningiomas. J. Neurosurg., 86, 853-858.
85. Stemmer-Rachamimov, A.O., Gonzalez-Agosti, C., Xu, L., Burwick, J.A., Beauchamp, R., Pinney, D., Louis, D.N. and Ramesh, V. (1997). Expression of NF2-encoded merlin and related ERM family proteins in the human central nervous system. J. Neuropath. Exper. Neuro., 56, 735-742.
86. Todo, T., Adams, E.F., Fahlbusch, R., Dingermann, T. and Werner, H. (1996). Autocrine growth stimulation of human meningioma cells by platelet derived growth factor. J. Neurosurg., 84, 852-858.
87. Trofatter, J.A., MacCollin, M.M., Rutter, J.L., Murrell, J.R., Duyao, M.P., Parry, D.M., Eldridge, R., Kley, N., Menon, A.G. and Pulaski, K., (1993). A novel Moesin-, Ezrin-, Radixin-like gene is a candidate for the neurofibromatosis tumor suppressor. Cell, 72, 791-800.
88. Tsukita, S., Yonemura, S. and Tsukita, S. (1997). ERM proteins: Head-to-tail regulation of actin - plasma membrane interaction. Trends Biochem. Sci., 22, 53-58.
89. Wang, S. and Vos, J.M. (1996). A hybrid herpes virus infectious vector based on Epstein-Barr virus and Herpes Simplex Virus Type 1 for gene transfer into human cells in vitro and in vivo. J. Virol, 70, 8422-8430.
90. Wang, Y., Krushel, L.A. and Edelman, G.M. (1996). Targeted DNA recombination in vivo using an adenovirus carrying the cre recombinase gene. Proc. Natl. Acad. Sci. USA, 93, 3932-3936.
91. Weinstein, D.E., Burrola, P.G. and Lemke, G. (1995). Premature Schwann cell differentiation and hypermyelination in mice expressing a targeted antagonist of the POU transcription factor SCIP. Molecular and Cellular Neurosciences, 6(3), 212-229.
92. Wellenreuther, R., Kraus, J.A., Lenartz, D., Menon, A., Schramm, J., Louis, D.N., Ramesh, V., Gusella, J.F., Wiestler, O.D. and von Deimling, A. (1995). Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma Am. J. Pathol., 146, 827-832.
93. Yung, W.K., Kyritsis, A.P., Gleason, M.J. and Levin, V.A. (1996). Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid. Clin. Cancer Res. 2, 1931-1935.
94. Zorick, T.S. and Lemke, G. (1996). Schwann cell differentiation. Curr. Opin. Cell Biol., 8, 870-876.
95. J. Neurogenelics, Vol. 14(2), pp. 107-123